Company Overview and News

Troubled Telit faces financial watchdog investigation

Troubled “internet of things” firm Telit Communications is being investigated by Britain’s financial watchdog in a further blow to the scandal-hit company.
Upvote Downvote

Scandal-hit Telit secures new bank covenants after tough 2017

Scandal-hit “internet of things” firm Telit Communications has agreed new covenant deals with its banks and warned its profits will be lower than expected after a tough 2017.
Upvote Downvote

Top Technology Dividend Picks TiVo, Camtek, American And Magic Software Shoot At 24-88% December Gains Per Broker Targets

2017-12-27 seekingalpha
Top Technology ten by broker estimated net gains, ASOZY, ASOZF, CSYJY, IBM, ASX, XRX, MGIC, AMSWA, CAMT, & TIVO, averaged 23.36%, calculated 12/22/17.
Upvote Downvote

RADA Electronic Industries' (RADA) CEO Dov Sella on Q3 2017 Results - Earnings Call Transcript

2017-11-28 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the RADA Electronic Industries Third Quarter 2017 Results Conference Call. All participants are present in listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. As a reminder, this conference is being recorded.
Upvote Downvote

Market report: Telit Communications sinks on profit warning

The financial thriller developing at “internet of things” firm Telit Communications took another twist today after it issued another profit warning and admitted that concerns have been raised about its new chief executive’s share trading just months after its old boss left on the emergence of a historic fraud case.
Upvote Downvote

Mark Carney set to write inflation failure letter

Bank of England governor Mark Carney could have to write a letter to the Chancellor this morning to explain why the Monetary Policy Committee has allowed inflation to stray so far from its 2pc target rate.
Upvote Downvote

The week ahead in business and finance

Ladbrokes Coral’s update is considered largely academic to investors as bricks-and-mortar bookies await their fate in the Government’s review into the gambling sector. A 12-week consultation, which began last month, will decide how low the maximum stake in FOBTs will be with a £2 verdict from its current £100 limit considered disastrous for the likes of Ladbrokes and William Hill.
Upvote Downvote

Market report: Burberry fall softened by activist investor upping stake

Burberry’s strategy shift-induced freefall on the FTSE 100 came to a sudden halt after revered Belgian activist investor Alfred Frère seized the opportunity to snap up the fashion house’s shares on the cheap following its two-day plunge.
Upvote Downvote

PRESS DIGEST- British Business - Nov 3

2017-11-03 reuters
Nov 3 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
Upvote Downvote

Top Tech Dividend Dogs Xperi, TiVo, PCTEL, & LSI Shoot For Over 20% October Gains Per Broker Targets

2017-10-19 seekingalpha
Top Technology ten, CSCO, STX, IBM, ASX, AMSWA, QCOM, LYTS, PCTI, TIVO, & XPRI, by analyst estimated net gains, averaged 29.8%, calculated 10/13/17.
Upvote Downvote

Market report: Oil producers slide as tensions rise in Kurdish Iraq

Rising tensions in Kurdish Iraq drove down shares in exposed Genel Energy and Gulf Keystone Petroleum as the prospect of a supply squeeze in the oil-rich region pushed Brent crude above $58 per barrel.
Upvote Downvote

Telit and Husqvarna Collaborate on Robots for Urban Park Sustainability Program

2017-10-10 prnewswire
Telit's end-to-end IoT solutions are enabling real-time sensor data from robotic lawnmowers that offers valuable insight into green-space environmental conditions and park maintenance
Upvote Downvote

Telit Bluetooth Module Selected for 270 Vision BPMpro Sensor

2017-10-09 prnewswire
- BlueMod+SR delivers competitive advantage of first to market for 270 Vision's BPMpro Mark 2 wearable sensor for remote patient monitoring - Class 1 Medical device streams post-surgery range-of-motion data, accelerating patient rehabilitation and cutting post-operative costs
Upvote Downvote

Telit Teams with Wind River to Accelerate Industrial IoT Adoption

2017-10-03 prnewswire
LONDON, Oct. 3, 2017 /PRNewswire/ -- Telit, a global enabler of the Internet of Things (IoT), today announced it is collaborating with Wind River®, an Intel® company, to accelerate Industrial IoT (IIoT) adoption. Through this relationship, Telit and Wind River are reducing the complexities of IoT device management, helping companies quickly and securely realize the full solution benefits of IIoT.
Upvote Downvote

Telit Selected by VAIO for Industry's First 450 Mbps Mobile Data Enabled Notebooks

2017-09-25 prnewswire
- Single SKU, worldwide solution simplfies logistics, inventory management, and global deployment for OEMs - Telit's new LN94x M.2 mobile data card family supports LTE Cat 6, 9, and 11 to immediately address broad mobile computing OEM market needs
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...